AgomAb Therapeutics NV SEC filings AGMB

AgomAb Therapeutics NV has 49 filings in SEC EDGAR's recent list, going back to Jun 20, 2024. Its latest annual report, Form 20-F, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 13, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
6-K Current report (foreign issuer) Oct 13, 2026 Oct 13, 2026
6-K Current report (foreign issuer) Oct 1, 2026 Oct 1, 2026
6-K Current report (foreign issuer) Sep 14, 2026 Sep 14, 2026
6-K Current report (foreign issuer) Sep 11, 2026 Sep 11, 2026
6-K Current report (foreign issuer) Aug 10, 2026 Aug 10, 2026
6-K Current report (foreign issuer) Aug 6, 2026 Aug 6, 2026
6-K Current report (foreign issuer) Jun 23, 2026 Jun 23, 2026
6-K Current report (foreign issuer) May 27, 2026 May 27, 2026
6-K Current report (foreign issuer) Apr 24, 2026 Apr 24, 2026
6-K Current report (foreign issuer) Mar 5, 2026 Mar 5, 2026
6-K Current report (foreign issuer) Feb 9, 2026 Feb 9, 2026

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
AGMB (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Belgium
Headquarters
Antwerpen
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
2020932

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.